Ethyl 2,6-Dichloro-5-Fluoro-Pyridine-3-Acetoacetate

We are Ethyl 2,6-Dichloro-5-Fluoro-Pyridine-3-Acetoacetate CAS:96568-04-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  Ethyl 2,6-Dichloro-5-Fluoro-Pyridine-3-Acetoacetate
CAS.NO:96568-04-6
Synonyms:
3-Pyridinebutanoic acid, 2,6-dichloro-5-fluoro-β-oxo-, ethyl ester
Ethyl 4-(2,6-dichloro-5-fluoro-3-pyridinyl)-3-oxobutanoate
Ethyl 4-(2,6-dichloro-5-fluoropyridin-3-yl)-3-oxobutanoate
ethyl 3-(2,6-dichloro-5-fluoropyridin-3-yl)-3-oxopropanoate

Molecular Formula:C11H10Cl2FNO3
Molecular Weight:294.10600

Physical and Chemical Properties:
Density: 1.434 g / cm3
Boiling point: 349.9ºC at 760 mmHg
Melting point: 68-72 ° C (lit.)
Flash point: 165.4ºC
Refractive index: 1.524

Specification:
Appearance:white or off-white powder
Purity:≥98.5%
Impurities:≤0.6%
Loss on drying:≤0.5% 

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:
Intermediates of Gemifioxacin mesylate CAS:210353-53-0

Ethyl 2,6-Dichloro-5-Fluoro-Pyridine-3-Acetoacetate


Related News: In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.2-Amino-5-bromo-3-nitropyridine In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethanamine CAS:608141-42-0 The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.1161009-88-6 The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.

Related Products
Product Name
4-Methylsulphonyl benzaldehyde View Details
2-Phosphonobutane -1,2,4-Tricarboxylic Acid View Details
7-Methoxy-1-naphthylacetonitrile View Details
1,7-Dibromonaphthalene Cas:58258-65-4 manufacturer 1-(benzotriazol-1-yl)octan-1-one manufacturer 1-Bromo-2,3-epoxypropane manufacturer 2-Nitro-N-Hydroxyethyl Aniline manufacturer 1-Chloro-1,1-difluoroethane Cas:75-68-3 manufacturer